These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 2597314)
1. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. Fornstedt B; Brun A; Rosengren E; Carlsson A J Neural Transm Park Dis Dement Sect; 1989; 1(4):279-95. PubMed ID: 2597314 [TBL] [Abstract][Full Text] [Related]
2. Oxidation of dopamine and related catechols in dopaminergic brain regions in Parkinson's disease and during ageing in non-Parkinsonian subjects. Fornstedt Wallin B J Neural Transm (Vienna); 2024 Mar; 131(3):213-228. PubMed ID: 38238531 [TBL] [Abstract][Full Text] [Related]
3. Effects of inhibition of monoamine oxidase on the levels of 5-S-cysteinyl adducts of catechols in dopaminergic regions of the brain of the guinea pig. Fornstedt B; Carlsson A Neuropharmacology; 1991 May; 30(5):463-8. PubMed ID: 1907723 [TBL] [Abstract][Full Text] [Related]
4. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. Zhang F; Dryhurst G J Med Chem; 1994 Apr; 37(8):1084-98. PubMed ID: 7909337 [TBL] [Abstract][Full Text] [Related]
5. In vivo autoxidation of dopamine in guinea pig striatum increases with age. Fornstedt B; Pileblad E; Carlsson A J Neurochem; 1990 Aug; 55(2):655-9. PubMed ID: 2370552 [TBL] [Abstract][Full Text] [Related]
6. Norepinephrine and its metabolites are involved in the synthesis of neuromelanin derived from the locus coeruleus. Wakamatsu K; Tabuchi K; Ojika M; Zucca FA; Zecca L; Ito S J Neurochem; 2015 Nov; 135(4):768-76. PubMed ID: 26156066 [TBL] [Abstract][Full Text] [Related]
7. Neurochemical studies on central dopamine neurons--regional characterization of dopamine turnover. Hallman H; Jonsson G Med Biol; 1984; 62(3):198-209. PubMed ID: 6492900 [TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927 [TBL] [Abstract][Full Text] [Related]
9. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra. Nissbrandt H; Engberg G; Pileblad E Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):16-28. PubMed ID: 1663587 [TBL] [Abstract][Full Text] [Related]
10. Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy. Goldstein DS; Sullivan P; Holmes C; Mash DC; Kopin IJ; Sharabi Y Parkinsonism Relat Disord; 2017 Feb; 35():88-91. PubMed ID: 28034624 [TBL] [Abstract][Full Text] [Related]
11. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. Spencer JP; Jenner P; Daniel SE; Lees AJ; Marsden DC; Halliwell B J Neurochem; 1998 Nov; 71(5):2112-22. PubMed ID: 9798937 [TBL] [Abstract][Full Text] [Related]
12. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Fornstedt B; Rosengren E; Carlsson A Neuropharmacology; 1986 Apr; 25(4):451-4. PubMed ID: 3086766 [TBL] [Abstract][Full Text] [Related]
13. Turnover of dopamine and dopamine metabolites in rat brain: comparison between striatum and substantia nigra. Nissbrandt H; Carlsson A J Neurochem; 1987 Sep; 49(3):959-67. PubMed ID: 3612134 [TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. Kumar AM; Fernandez JB; Singer EJ; Commins D; Waldrop-Valverde D; Ownby RL; Kumar M J Neurovirol; 2009 May; 15(3):257-74. PubMed ID: 19499455 [TBL] [Abstract][Full Text] [Related]
15. DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease. Cai W; Wakamatsu K; Zucca FA; Wang Q; Yang K; Mohamadzadehonarvar N; Srivastava P; Tanaka H; Holly G; Casella L; Ito S; Zecca L; Chen X Prog Neurobiol; 2023 Apr; 223():102414. PubMed ID: 36746222 [TBL] [Abstract][Full Text] [Related]
17. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Gerhardt GA; Cass WA; Huettl P; Brock S; Zhang Z; Gash DM Brain Res; 1999 Jan; 817(1-2):163-71. PubMed ID: 9889359 [TBL] [Abstract][Full Text] [Related]
18. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sirinathsinghji DJ; Whittington PE; Audsley AR Brain Res; 1986 Dec; 399(2):339-45. PubMed ID: 2435361 [TBL] [Abstract][Full Text] [Related]
19. Effects of d-amphetamine on dopaminergic neurotransmission; a comparison between the substantia nigra and the striatum. Elverfors A; Nissbrandt H Neuropharmacology; 1992 Jul; 31(7):661-70. PubMed ID: 1328918 [TBL] [Abstract][Full Text] [Related]
20. Evidence that the substantia nigra is a site of action for L-DOPA. Robertson GS; Robertson HA Neurosci Lett; 1988 Jun; 89(2):204-8. PubMed ID: 3393296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]